July 12 (Reuters) - Vaccibody AS VACC-ME.OL :
* VACCIBODY ENTERS INTO WORLDWIDE LICENSE AGREEMENT WITH
ADAPTIVE
* VACCIBODY AND ADAPTIVE BIOTECHNOLOGIES HAVE ENTERED INTO
EXCLUSIVE AGREEMENT FOR USE OF ADAPTIVE'S VALIDATED SARS-COV-2 T
CELL EPITOPES
* VACCIBODY WILL USE SELECTED SET OF THESE SARS-COV-2 T CELL
EPITOPES IN ITS SECOND-GENERATION SARS-COV-2 VACCINE TRIAL,
PLANNED FOR Q4 2021
Source text for Eikon: ID:nObiVfwMVa
Further company coverage: VACC-ME.OL
((Reuters.Briefs@thomsonreuters.com;))